OncoSNIPE - Study of Molecular Profiles Associated With the Development of Resistance in Solid Cancer Patients

Inclusion Criteria:

1. General

   * Adult patient, 18 years of age or older
   * Naive chemo patient
   * Performant status: 0,1 or 2.
   * Life expectancy\> 3 months
   * Subject affiliated to a social security and health insurance scheme
   * Subject having dated and signed informed consent
   * For women of childbearing age (negative pregnancy test): effective contraception
2. Pancreatic cancer:

   * Patient receiving a biopsy, as part of the usual care of the patient:

     * Either from the primary tumor
     * Either a metastasis for a strong suspicion of locally advanced or metastatic pancreatic ductal adenocarcinoma;
   * With advanced or metastatic tumors (liver, lungs, peritoneum, others) that cannot benefit from local or locoregional treatment;
   * Presence of target lesion (s) measurable according to RECIST criteria
   * Patient who cannot be treated by surgery or radiotherapy
3. Lung cancer:

   * Patient with histologically proven non-small cell lung cancer
   * Locally advanced stage IIIB or IV
   * Treatment with chemotherapy, targeted therapy, immunotherapy
   * Tissue available after analysis of the usual biomarkers in the event of a non-epidermoid tumor
   * Rate of tumor cells observed on biopsies must be ≥ 30%.
   * Presence of measurable target lesion or disease assessable according to RECIST criteria
4. Breast cancer:

   * Breast cancer of recent diagnosis, histologically proven.
   * Triple negative breast cancer: negativity of estrogen and progesterone receptors in the tumor (\<10%), absence of HER2 overexpression according to the IHC classification (score 0 or 1+) and / or FISH negative
   * or
   * LumB: RO positive, RP positive or negative, HER2 negative, high proliferation;
   * Stage I to III for triple negative breast cancer (including stage T4d = inflammatory cancer), Stage II or III of the UICC classification for LumB
   * Non-metastatic patient (M0 according to TNM classification)
   * Rate of tumor cells observed on biopsies must be ≥ 30%
   * Patient who cannot be treated exclusively by surgery or radiotherapy

Exclusion Criteria:

General

* History of chemotherapy (except adjuvant completed for more than at least 6 months) or radiotherapy
* Patient whose monitoring and treatment will not be carried out in the study health establishments;
* Tumor not histologically proven;
* Life expectancy of less than 3 months
* Pregnancy or breastfeeding
* Refusal to participate in the trial
* Persons deprived of their liberty, persons under guardianship or curatorship
* Inability to submit to the medical follow-up of the test for social or psychological reasons
* No affiliation to a social security scheme or state medical aid (AME) or universal medical coverage (CMU)
* Any condition for which participation in the protocol would present a risk or which would not make it possible to comply with the requirements of the protocol according to the investigator
* History of other cancers in the last 5 years except cervical cancer and skin cancer of the basal or epidermoid cells treated
* Known HIV seropositivity Specific

Pancreatic cancer:

* Other histologies: neuroendocrine cancer, acinar cancer, pancreatic metastasis of another cancer
* Patient who cannot benefit from chemotherapy (Performans status (PS) 3 - 4);
* Other progressive cancer during the management of pancreatic cancer;